Long-term activation of adenosine monophosphate-activated protein kinase attenuates pressure-overload-induced cardiac hypertrophy

Journal of Cellular Biochemistry

Volumn 100, Issue 5, 2007, Pages 1086-1099

  Li, Hong Liang ^a,b   Yin, Ran ^c   Chen, Dandan ^c   Liu, Dan ^c   Wang, Dong ^d   Yang, Qinglin ^e   Dong, Yu Gang ^c  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b HARVARD MEDICAL SCHOOL   (United States)

^c THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^d UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^e MOREHOUSE SCHOOL OF MEDICINE   (United States)

Author keywords

AMPK; Cardiac hypertrophy; NF B; NFAT

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; CALCINEURIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR NFAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVATION; ENZYME MECHANISM; HEART VENTRICLE HYPERTROPHY; IN VITRO STUDY; IN VIVO STUDY; LONG TERM CARE; MALE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RAT; SIGNAL TRANSDUCTION;

AMINOIMIDAZOLE CARBOXAMIDE; ANIMALS; ANIMALS, NEWBORN; CALCINEURIN; CARDIOMEGALY; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HYPOGLYCEMIC AGENTS; MALE; MITOGEN-ACTIVATED PROTEIN KINASES; MULTIENZYME COMPLEXES; MYOCYTES, CARDIAC; NF-KAPPA B; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; RATS; RATS, SPRAGUE-DAWLEY; RIBONUCLEOTIDES; SIGNAL TRANSDUCTION; VENTRICULAR PRESSURE;

RATTUS;

EID: 33947574510     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21197     Document Type: Article

References (36)

1. Behr TM, Nerurkar SS, Nelson AH, Coatney RW, Woods TN, Sulpizio A, Chandra S, Brooks DP, Kumar S, Lee JC, Ohlstein EH, Angermann CE, Adams JL, Sisko J, Sackner-Bernstein JD, Willette RN. 2001. Hypertensive end-organ damage and premature mortality are p38 mitogen-activated protein kinase-dependent in a rat model of cardiac hypertrophy and dysfunction. Circulation 11:1292-1298.
2. Bolster DR, Crozier SJ, Kimball SR, Jefferson LS. 2002. AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signaling. J Biol Chem 277:23977-23980.
3. Brown JH, Del Re DP, Sussman MA. 2006. The Rac and Rho hall of fame: A decade of hypertrophic signaling hits. Circ Res 98:730-742.
4. Buhl ES, Jessen N, Pold R, Ledet T, Flyvbjerg A, Pedersen SB, Pedersen O, Schmitz O, Lund S. 2002. Long-term AICAR administration reduces metabolic disturbances and lowers blood pressure in rats displaying features of the insulin resistance syndrome. Diabetes 51:2199-2206.
5. Cacicedo JM, Yagihashi N, Keaney JF, Jr., Ruderman NB, Ido Y. 2004. AMPK inhibits fatty acid-induced increases in NF-kappaB transactivation in cultured human umbilical vein endothelial cells. Biochem Biophys Res Commun 324:1204-1209.
6. Chan AY, Dyck JR. 2005. Activation of AMP-activated protein kinase (AMPK) inhibits protein synthesis: A potential strategy to prevent the development of cardiac hypertrophy. Can J Physiol Pharmacol 83:24-28.
7. Chan AY, Soltys CL, Young ME, Proud CG, Dyck JR. 2004. Activation of AMP-activated protein kinase inhibits protein synthesis associated with hypertrophy in the cardiac myocyte. J Biol Chem 279:32771-32779.
8. Diez J, Gonzalez A, Lopez B, Querejeta R. 2005. Mechanisms of disease: Pathologic structural remodeling is more than adaptive hypertrophy in hypertensive heart disease. Nat Clin Pract Cardiovasc Med 2:209-216.
9. Dorn GW II, Force T. 2005. Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest 115: 527-537.
10. Giri S, Nath N, Smith B, Viollet B, Singh AK, Singh I. 2004. 5-Aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside inhibits proinflammatory response in glial cells: A possible role of AMP-activated protein kinase. J Neurosci 24:479-487.
11. Gonzalez AA, Kumar R, Mulligan JD, Davis AJ, Weindruch R, Saupe KW. 2004. Metabolic adaptations to fasting and chronic caloric restriction in heart, muscle, and liver do not include changes in AMPK activity. Am J Physiol Endocrinol Metab 287:E1032-E1037.
12. Hattori Y, Akimoto K, Nishikimi T, Matsuoka H, Kasai K. 2006. Activation of AMP-activated protein kinase enhances angiotensin ii-induced proliferation in cardiac fibroblasts. Hypertension 47:265-270.
13. Igata M, Motoshima H, Tsuruzoe K, Kojima K, Matsumura T, Kondo T, Taguchi T, Nakamaru K, Yano M, Asano T, Nishikawa T, Araki E. 2005. Adenosine monophosphate-activated protein kinase suppresses vascular smooth muscle cell proliferation through the inhibition of cell cycle progression. Circ Res 97:837-844.
14. Inoki K, Zhu T, Guan KL. 2003. TSC2 mediates cellular energy response to control cell growth and survival. Cell 115:577-590.
15. Kim S, Ohta K, Hamaguchi A, Yukimura T, Miura K, Iwao H. 1995. Angiotensin II induces cardiac phenotypic modulation and remodeling in vivo in rats. Hypertension 25:1252-1259.
16. Li HL, Wang AB, Huang Y, Liu DP, Wei C, Williams GM, Zhang CN, Liu G, Liu YQ, Hao DL, Hui RT, Lin M, Liang CC. 2005. Isorhapontigenin, a new resveratrol analog, attenuates cardiac hypertrophy via blocking signaling transduction pathways. Free Radic Biol Med 38:243-257.
17. Li HL, Huang Y, Zhang CN, Liu G, Wei YS, Wang AB, Liu YQ, Hui RT, Wei C, Williams GM, Liu DP, Liang CC. 2006. Epigallocathechin-3 gallate inhibits cardiac hypertrophy through blocking reactive oxidative species-dependent and -independent signal pathways. Free Radic Biol Med 40:1756-1777.
18. Molkentin JD. 2004. Calcineurin-NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs. Cardiovasc Res 63:467-475.
19. Morrow VA, Foufelle F, Connell JM, Petrie JR, Gould GW, Salt IP. 2003. Direct activation of AMP-activated protein kinase stimulates nitric-oxide synthesis in human aortic endothelial cells. J Biol Chem 278:31629-31639.
20. Muslin AJ. 2005. Role of raf proteins in cardiac hypertrophy and cardiomyocyte survival. Trends Cardiovasc Med 15:225-229.
21. Nakagawa O, Ogawa Y, Itoh H, Suga S, Komatsu Y, Kishimot I, Nishino K, Yoshimasa T, Nakao K. 1995. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an "emergency" cardiac hormone against ventricular overload. J Clin Invest 96:1280-1287.
22. Nakano H. 2004. Signaling crosstalk between NF-kappaB and JNK. Trends Immunol 25:402-405.
23. Natoli G, Saccani S, Bosisio D, Marazzi I. 2005. Interactions of NF-kappaB with chromatin: The art of being at the right place at the right time. Nat Immunol 6:439-445.
24. Papa S, Zazzeroni F, Pham CG, Bubici C, Franzoso G. 2004. Linking JNK signaling to NF-kappaB: A key to survival. J Cell Sci 117:5197-5208.
25. Proud CG. 2004. Ras, PI3-kinase and mTOR signaling in cardiac hypertrophy. Cardiovasc Res 63:403-413.
26. Quan H, Athirakul K, Wetsel WC, Torres GE, Stevens R, Chen YT, Coffman M, Caron MG. 2004. Hypertension and impaired glycine handling in mice lacking the orphan transporter XT2. Mol Cell Biol 24:4166-4173.
27. Rattan R, Giri S, Singh AK, Singh I. 2005. 5-Aminoimidazole-4- carboxamide-1-beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. J Biol Chem 280:39582-39593.
28. Reiter AK, Bolster DR, Crozier SJ, Kimball SR, Jefferson LS. 2005. Repression of protein synthesis and mTOR signaling in rat liver mediated by the AMPK activator aminoimidazole carboxamide ribonucleoside. Am J Physiol Endocrinol Metab 288:E980-E988.
29. Tian R, Musi N, D'Agostino J, Hirshman MF, Goodyear LJ. 2001. Increased adenosine monophosphate-activated protein kinase activity in rat hearts with pressure-overload hypertrophy. Circulation 104:1664-1669.
30. Tokudome T, Horio T, Kishimoto I, Soeki T, Mori K, Kawano Y, Kohno M, Garbers DL, Nakao K, Kangawa K. 2005. Calcineurin-nuclear factor of activated T cells pathway-dependent cardiac remodeling in mice deficient in guanylyl cyclase A, a receptor for atrial and brain natriuretic peptides. Circulation 111:3095-3104.
31. Wang Y, Su B, Sah VP, Brown JH, Han J, Chien KR. 1998. Cardiac hypertrophy induced by mitogen-activated protein kinase kinase 7, a specific activator for c-Jun NH2-terminal kinase in ventricular muscle cells. J Biol Chem 273:5423-5426.
32. Wilkins BJ, Molkentin JD. 2004. Calcium-calcineurin signaling in the regulation of cardiac hypertrophy. Biochem Biophys Res Commun 322:1178-1191.
33. Xiao L, Pimental DR, Amin JK, Singh K, Sawyer DB, Colucci WS. 2001. MEK1/2-ERK1/2 mediates alpha1-adrenergic receptor-stimulated hypertrophy in adult rat ventricular myocytes. J Mol Cell Cardiol 33:779-787.
34. Yue TL, Gu JL, Wang C, Reith AD, Lee JC, Mirabile RC, Kreutz R, Wang Y, Maleeff B, Parsons AA, Ohlstein EH. 2000. Extracellular signalregulated kinase plays an essential role in hypertrophic agonists, endothelin-1 and phenylephrine-induced cardiomyocyte hypertrophy. J Biol Chem 275:37895-37901.
35. Zou MH, Hou XY, Shi CM, Nagata D, Walsh K, Cohen RA. 2002. Modulation by peroxynitrite of Akt- and AMP-activated kinase-dependent Ser1179 phosphorylation of endothelial nitric oxide synthase. J Biol Chem 277: 32552-32557.
36. Zou MH, Hou XY, Shi CM, Kirkpatick S, Liu F, Goldman MH, Cohen RA. 2003. Activation of 5′-AMP-activated kinase is mediated through c-Src and phosphoinositide 3-kinase activity during hypoxia-reoxygenation of bovine aortic endothelial cells. Role of peroxynitrite. J Biol Chem 278:34003-34010.